Pioneering Disease Solutions

American Gene Technologies® is a private biotechnology company supported by accredited investors. The company develops genetic medicines that address unmet medical needs in inherited or acquired diseases through the application of viral vector technology. American Gene Technologies is pioneering disease solutions to achieve permanent cures for human diseases.

The Future of Medicine

American Gene Technologies is focused on creating long-term value for patients, society, investors and donors by developing and testing cutting-edge gene therapies to cure some of humanity’s worst diseases. American Gene Technologies HIV cure clinical trial could not only lead to a blockbuster drug that brings relief to one of society's most elusive epidemics, but it could prove the efficiency and effectiveness of American Gene Technologies platform technologies to cure dozens of diseases ranging from viruses to cancers.

1 Barry Wells - Green

Barry H. Wells, MD

Investor Relations

The Gene & Cell Therapy Industry Is
Poised for Enormous Growth

Current gene and cell therapies are just the tip of a $5 trillion market.
According to Goldman Sachs, the gene and cell therapy industry could become 4X the size of the current pharmaceutical market.

Lead Programs & Pipeline

AGT103-T, our HIV therapeutic, is currently in Phase 1 clinical trials, and we expect to see the lead candidates in our Immuno-oncology and Phenylketonuria (PKU) programs move into the clinic in the next few years.

U.S. Patents & FDA Designations

American Gene Technologies HIV, PKU and Cancer technologies are covered by an extensive patent portfolio.

 DLA Piper Global Law Firm and Snell and Wilmer serve as American Gene patent counsels. 


In addition, American Gene has been granted FDA Orphan Drug Designation for its treatment of PKU.

HIV Cure Program: Phase 1 Human Trial Accelerates

07_AGT Investor Page HIV Video #1

AGT ™successfully submitted its Investigational New Drug (IND) application to the Food & Drug Administration (FDA) to begin a Phase 1 clinical trial for its genetically modified autologous cell therapy for HIV.

08_AGT Investor Page HIV Video #2

A Montgomery County-based biotechnology company has announced it received approval from the FDA to begin human trials for its HIV cure program. American Gene Technologies has been developing its program for 12 years. ABC7 News reports on the historic milestone.

09_AGT Investor Page HIV Video #3

American Gene Technologies announces the treatment of the first participant in its Phase I clinical trial to evaluate the safety of the cell and gene therapy product AGT103-T.

10_AGT Investor Page HIV Video #4

The Data and Safety Monitoring Board (DSMB) voted unanimously to continue American Gene Technologies HIV Cure Program without modification after safety analysis of the first participant’s data revealed no adverse effects from the treatment AGT103-T.

HIV Program Milestones

website milestones-01

HIV Program Milestones

website milestones mobile-01 1

Third-Party Reports on

American Gene Technologies

American Gene Technologies hosted an analyst day to provide insight into the status of HIV therapy, including cure research, which provides a context for understanding the unique features and advantages of the company's AGT103-T cell and gene therapy for HIV. The event was hosted shortly before the IND was submitted.

Hosted By American Gene Technologies

American Gene Technologies is followed by the analyst listed above. Please note that any opinions, estimates or forecasts regarding American Gene Technologies performance made by the analyst are his alone and do not represent opinions, forecasts or predictions of American Gene Technologies or its management. American Gene Technologies does not, by its reference above or distribution, imply its endorsement of or concurrence with such information, conclusions or recommendations.

Latest News on HIV Clinical Trial Progress

19_AGT Investor Page Green Check

The cell and gene therapy product AGT103-T was evaluated for safety, immunogenicity, and persistence for up to 180 days post infusion. We sought to investigate the impact following analytical treatment interruptions (ATIs)

07_AGT HIV Page Yellow Check

We conducted a Phase 1a clinical study that evaluated the safety and durability of AGT103-T in seven people living with HIV. We also sought to evaluate the durability of the modified cells.

21_AGT Investor Page Red Check

This is a pivotal step to potentially demonstrating a gene therapy cure for HIV.

17_AGT Investor Page Blue Check

First Three Participants Showed No Serious Adverse Events

18_AGT Investor Page Teal Check

First Participant Was Infused With AGT103-T

We're happy to help

Contact Us

1 Barry Wells - Green

Primary IR Contact

Barry H. Wells, MD

Business Development,

Investor Relations

Sign-up For Our Newsletter

We send out quarterly newsletters that keep you up-to-date on all our projects, progress, and events.